Rigel Pharmaceuticals, Inc. (RIGL)
47.15
+0.18
(+0.38%)
USD |
NASDAQ |
Oct 02, 16:00
47.12
-0.03
(-0.06%)
After-Hours: 20:00
Rigel Pharmaceuticals Gross Profit Margin (Quarterly) : 89.17% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 89.17% |
| March 31, 2026 | 92.17% |
| December 31, 2025 | 91.47% |
| September 30, 2025 | 93.16% |
| June 30, 2025 | 95.57% |
| March 31, 2025 | 91.73% |
| December 31, 2024 | 89.95% |
| September 30, 2024 | 85.49% |
| June 30, 2024 | 92.38% |
| March 31, 2024 | 93.14% |
| December 31, 2023 | 89.41% |
| September 30, 2023 | 95.49% |
| June 30, 2023 | 96.00% |
| March 31, 2023 | 96.25% |
| December 31, 2022 | 99.33% |
| September 30, 2022 | 98.88% |
| June 30, 2022 | 96.53% |
| March 31, 2022 | 98.57% |
| December 31, 2021 | 95.63% |
| September 30, 2021 | 98.09% |
| June 30, 2021 | 98.53% |
| March 31, 2021 | 99.61% |
| December 31, 2020 | 98.26% |
| September 30, 2020 | 87.26% |
| June 30, 2020 | 85.60% |
| Date | Value |
|---|---|
| March 31, 2020 | 99.57% |
| December 31, 2019 | 98.26% |
| September 30, 2019 | 98.51% |
| June 30, 2019 | 97.01% |
| March 31, 2019 | 98.50% |
| December 31, 2018 | 99.50% |
| September 30, 2018 | 95.31% |
| June 30, 2018 | 89.42% |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | 0.00% |
| June 30, 2017 | |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Cytokinetics, Inc. | 67.78% |
| Ironwood Pharmaceuticals, Inc. | 99.60% |
| Capricor Therapeutics, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 113.6% |
| Return on Assets | 79.07% |
| Return on Invested Capital | 95.96% |
| Profit Margin (Quarterly) | 21.97% |
| Operating Margin (Quarterly) | 29.95% |
| Return on Net Operating Assets | 299.6% |